NU 2022-219
INVENTORS
SHORT DESCRIPTION
A formulation of anaerobic bacteria embedded in embolic material, delivered through transcatheter intra-arterial infusion for treating solid tumors.
BACKGROUND
Non-pathogenic Clostridium novyi (C. novyi-NT) is an anaerobic bacterium capable of selective germination in hypoxic tissues, leading to the targeted destruction of tumor cells without causing substantial host toxicity. While animal studies and human clinical trials have shown promising oncolytic potential through intravenous and intra-tumoral injections of C. novyi, substantial efforts are required to optimize both safety and efficacy aspects of this bacteriolytic paradigm.
ABSTRACT
Northwestern researchers have developed a new formulation of C. novyi spores immobilized within calcium alginate microspheres. The formulation employs temporary embolization to induce tumor hypoxia, rendering the sites susceptible to oncolysis. Subsequent germination and release of bacterium spores in their functional vegetative form initiates anti-tumor response in tumors. In animal studies, Dr. Dong-Hyun Kim’s lab showed that transcatheter intra-arterial infusion of this formulation expands the viable C. novyi area that are cytotoxic to cancerous tissues, stimulates host immune responses against tumor, and augments anti-cancer effects. The formulation is simple, safe, and compatible with immunotherapies, offering smart control of bacterial germination that appears to address the current challenges with conventional C. novyi-based therapies.
APPLICATIONS
ADVANTAGES
IP STATUS
A PCT application has been filed.